Stratified Transplant Survival Metric for Cardiac Transplant Disorder

1
Effectiveness
1
Safety
Carnegie Mellon University, Pittsburgh, PA
Stratified Transplant Survival Metric - Other
Eligibility
18+
All Sexes
Eligible conditions
Cardiac Transplant Disorder

Study Summary

This study is evaluating whether transplant center performance data that reflect center donor acceptance rates influence patients and their family members to evaluate centers with high organ decline rates less favorably than centers with low organ decline rates

See full description

Treatment Effectiveness

Effectiveness Estimate

1 of 3

Study Objectives

This trial is evaluating whether Stratified Transplant Survival Metric will improve 1 primary outcome and 1 secondary outcome in patients with Cardiac Transplant Disorder. Measurement will happen over the course of 1 day.

1 day
Hospital Choice
Mediator of Hospital Choice

Trial Safety

Trial Design

3 Treatment Groups

No Control Group
Condition 2: Stratified Transplant Pictograph

This trial requires 400 total participants across 3 different treatment groups

This trial involves 3 different treatments. Stratified Transplant Survival Metric is the primary treatment being studied. Participants will be divided into 3 treatment groups. There is no placebo group. The treatments being tested are not being studied for commercial purposes.

Condition 2: Stratified Transplant Pictograph
Other
Participants randomized to Condition 2 will view only stratified transplant survival outcome information when making a choice between the two hospitals. The "survival following transplant" metric is displayed as a pair of survival rate pictographs corresponding to two distinct groups of transplant patients at the center: those who received optimal donor organs and those who received adequate donor organs.
Condition 4: Stratified Transplant SRTRParticipants randomized to Condition 4 will view only stratified transplant survival outcome information when making a choice between the two hospitals. The "survival following transplant" metric is displayed as a pair of quintile scores corresponding to two distinct groups of transplant patients at the center: those who received optimal donor organs and those who received adequate donor organs.
Condition 3: Combined Transplant SRTR
Other
Participants randomized to Condition 3 will view only combined transplant survival outcome information (e.g. transplant survival rate not stratified by number and quality of donor hearts accepted at each center) when making a choice between the two hospitals. The "survival following transplant" metric is displayed as a quintile score corresponding to all patients at the center who received transplants.

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 1 day
This trial has the following approximate timeline: 3 weeks for initial screening, variable treatment timelines, and roughly 1 day for reporting.

Who is running the study

Principal Investigator
G. C.
Prof. Gretchen Chapman, Professor
Carnegie Mellon University

Closest Location

Carnegie Mellon University - Pittsburgh, PA

Eligibility Criteria

This trial is for patients born any sex aged 18 and older. There are 5 eligibility criteria to participate in this trial as listed below.

Mark “yes” if the following statements are true for you:
Participants will be asked to participate if they confirm the following inclusion criteria in the consent form.
18 years of age or older
must read and understand the information in the consent form
must want to participate in the research and continue with the survey
must be a pre- or post-transplant patient or family member of the transplant patient

Patient Q&A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Can cardiac transplant disorder be cured?

Add answer

Symptoms related to transplant disorder often improve after transplanting and, in some cases, can be removed from the clinical record completely. Some cases of transplant discharge may be associated with transplant-associated rejection episodes.

Unverified Answer

What are common treatments for cardiac transplant disorder?

Add answer

Cardiac transplant has benefited from advances in surgical, immunosuppressant, and other strategies to reduce the complications of transplantation, including acute rejection and rejection leading to chronic rejection, organ rejection, transplant arteriosclerosis, cardiomyopathy, graft arteriosclerosis, and cardiac vascular disease. Although cardiac transplant therapy has improved, complications persist. The incidence of cardiac transplant, especially of transplant arteriosclerosis, continues to rise. As these complications occur more commonly, new strategies to reduce these consequences are warranted.

Unverified Answer

What causes cardiac transplant disorder?

Add answer

To prevent the development of cardiac transplant disorder, we recommend to: avoid administering medications with an increased risk for sudden death; prescribe drugs with low doses at the beginning of treatment; consider the possibility that an underlying problem could be caused by an unidentified allograft; perform cardiac function and viability tests before treatment starts.

Unverified Answer

What is cardiac transplant disorder?

Add answer

Cardiac transplant disorder represents the most common clinical course following cardiac transplantation with a hospital mortality of 10%. Because of the great importance of graft viability and transplant patient recovery, early diagnosis with diagnostic and therapeutic strategies tailored to each case are recommended.

Unverified Answer

What are the signs of cardiac transplant disorder?

Add answer

Although some of the signs and symptoms of transplant disorder may resemble those of rejection, such as increased liver activity, decreased white blood cell count, or increased body temperature, some of these signs and symptoms can be caused by other causes. In summary, the presence of signs and symptoms of transplant disorder does not automatically indicate rejection. These signs and symptoms can be mistaken for other problems such as pneumonia or pneumonia with anemia.

Unverified Answer

How many people get cardiac transplant disorder a year in the United States?

Add answer

A quarter of the patients who receive heart transplantation have post-transplant cardiac insufficiency at the time of transplantation. Transplant centers could expect about 25 new cases per year of cardiac transplant disorder after transplantation, assuming that the risk of cardiovascular death in patients with transplant cardiac insufficiency is the same as the general population.

Unverified Answer

Is stratified transplant survival metric typically used in combination with any other treatments?

Add answer

In this review, the term 'transplant survival metric' can be used to refer to stratified transplant survival outcomes. If stratified treatment outcomes are not being compared with any other treatment, they could be called 'combined transplant survival outcomes'. This is often referred to in clinical studies as 'combination transplant survival metrics' and this could be the metric of choice as such in future.

Unverified Answer

Have there been other clinical trials involving stratified transplant survival metric?

Add answer

This article presents survival data for transplant recipients from the current year that are stratified by presence and grade of post-transplant complications. This article, one of the first of its type, highlights the unique role that heart transplant outcomes have played in defining outcomes and as a clinical tool for management.

Unverified Answer

What does stratified transplant survival metric usually treat?

Add answer

The authors' stratified transplant survival metric was able to accurately predict renal transplant survival but did not predict renal allograft survival. This metric may be of use as a complementary method to other approaches, such as those designed to quantify rejection or rejection onset and duration.

Unverified Answer

What is the primary cause of cardiac transplant disorder?

Add answer

Patients without ischemic heart disease have a much better clinical course than those with ischemic heart disease. In conclusion, this study lends further support to the theory that there is a more benign course of the transplant patient with restrictive and obstructive cardiomyopathy and/or rejection and with no evidence of ischemia. In the setting of coronary artery disease these patients may have an increased risk of transplant dysfunction.

Unverified Answer

What are the common side effects of stratified transplant survival metric?

Add answer

Stratified transplant survival model can predict short and long-term transplant outcomes and thus stratify recipients. The model can help allocate donor organs more efficiently to candidates most likely to benefit.

Unverified Answer

What are the latest developments in stratified transplant survival metric for therapeutic use?

Add answer

Recently stratified mortality data demonstrates an improvement in stratified outcomes within the past decade for recipients and transplant-related deaths with more predictable survival outcomes with transplantation of adult patients.

Unverified Answer
See if you qualify for this trial
Get access to this novel treatment for Cardiac Transplant Disorder by sharing your contact details with the study coordinator.